287 related articles for article (PubMed ID: 27632203)
1. Changes in Antiemetic Overuse in Response to Choosing Wisely Recommendations.
Encinosa W; Davidoff AJ
JAMA Oncol; 2017 Mar; 3(3):320-326. PubMed ID: 27632203
[TBL] [Abstract][Full Text] [Related]
2. Prescription of Prophylactic Antiemetic Drugs for Patients Receiving Chemotherapy With Minimal and Low Emetic Risk.
Okuyama A; Nakamura F; Higashi T
JAMA Oncol; 2017 Mar; 3(3):344-350. PubMed ID: 27812688
[TBL] [Abstract][Full Text] [Related]
3. Characterizing and assessing antiemetic underuse in patients initiating highly emetogenic chemotherapy.
Mahendraratnam N; Farley JF; Basch E; Proctor A; Wheeler SB; Dusetzina SB
Support Care Cancer; 2019 Dec; 27(12):4525-4534. PubMed ID: 30915567
[TBL] [Abstract][Full Text] [Related]
4. 5-Hydroxytryptamine-3 receptor antagonist and dexamethasone as prophylaxis for chemotherapy-induced nausea and vomiting during moderately emetic chemotherapy for solid tumors: a multicenter, prospective, observational study.
Matsui R; Suzuki K; Takiguchi T; Nishio M; Koike T; Hayashi T; Seto T; Kogure Y; Nogami N; Fujiwara K; Kaneda H; Harada T; Shimizu S; Kimura M; Kenmotsu H; Shimokawa M; Goto K
BMC Pharmacol Toxicol; 2020 Oct; 21(1):72. PubMed ID: 33023657
[TBL] [Abstract][Full Text] [Related]
5. Antiemetic overuse in patients receiving chemotherapy.
Das M
Lancet Oncol; 2016 Oct; 17(10):e428. PubMed ID: 27667572
[No Abstract] [Full Text] [Related]
6. The safety of antiemetic medications for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Drug Saf; 2016; 15(3):343-56. PubMed ID: 26699406
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
8. Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study.
Hilarius DL; Kloeg PH; van der Wall E; van den Heuvel JJ; Gundy CM; Aaronson NK
Support Care Cancer; 2012 Jan; 20(1):107-17. PubMed ID: 21258948
[TBL] [Abstract][Full Text] [Related]
9. Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice.
Affronti ML; Schneider SM; Herndon JE; Schlundt S; Friedman HS
Support Care Cancer; 2014 Jul; 22(7):1897-905. PubMed ID: 24570103
[TBL] [Abstract][Full Text] [Related]
10. A retrospective review of antiemetic use for chemotherapy-induced nausea and vomiting in pediatric oncology patients at a tertiary care center.
Aseeri M; Mukhtar A; Al Khansa S; Elimam N; Jastaniah W
J Oncol Pharm Pract; 2013 Jun; 19(2):138-44. PubMed ID: 23034405
[TBL] [Abstract][Full Text] [Related]
11. Antiemetic medication for prevention and treatment of chemotherapy induced nausea and vomiting in childhood.
Phillips RS; Gopaul S; Gibson F; Houghton E; Craig JV; Light K; Pizer B
Cochrane Database Syst Rev; 2010 Sep; (9):CD007786. PubMed ID: 20824866
[TBL] [Abstract][Full Text] [Related]
12. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
13. Risk Model-Guided Antiemetic Prophylaxis vs Physician's Choice in Patients Receiving Chemotherapy for Early-Stage Breast Cancer: A Randomized Clinical Trial.
Clemons M; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Segal R; Dent S; Gertler S; Song X; Wheatley-Price P; Dranitsaris G
JAMA Oncol; 2016 Feb; 2(2):225-31. PubMed ID: 26562292
[TBL] [Abstract][Full Text] [Related]
14. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
15. Prescription trends of prophylactic antiemetics for chemotherapy-induced nausea and vomiting in Japan.
Okuyama A; Nakamura F; Higashi T
Support Care Cancer; 2014 Jul; 22(7):1789-95. PubMed ID: 24522743
[TBL] [Abstract][Full Text] [Related]
16. Guideline concordant care for prevention of acute chemotherapy-induced nausea and vomiting in children, adolescents, and young adults.
Beauchemin M; Sung L; Hershman DL; Weng C; Dupuis LL; Schnall R
Support Care Cancer; 2020 Oct; 28(10):4761-4769. PubMed ID: 31974769
[TBL] [Abstract][Full Text] [Related]
17. Palonosetron versus other 5-HT(3) receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with cancer on chemotherapy in a hospital outpatient setting.
Balu S; Buchner D; Craver C; Gayle J
Clin Ther; 2011 Apr; 33(4):443-55. PubMed ID: 21635990
[TBL] [Abstract][Full Text] [Related]
18. Oncologist perspectives on chemotherapy-induced nausea and vomiting (CINV) management and outcomes: A quantitative market research-based survey.
Aapro M; Ruffo P; Panteri R; Costa S; Piovesana V
Cancer Rep (Hoboken); 2018 Dec; 1(4):e1127. PubMed ID: 32729252
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the compliance with antiemetic guidelines for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancy.
Uchida M; Nakamura T; Shima T; Mori Y; Yoshimoto G; Kato K; Shimokawa M; Hosohata K; Miyamoto T; Akashi K
Pharmazie; 2019 Apr; 74(4):250-254. PubMed ID: 30940311
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of palonosetron versus other serotonin 5-HT3 receptor antagonists in triple antiemetic regimens during multiday highly emetogenic chemotherapy.
Kim KI; Lee DE; Cho I; Yoon JH; Yoon SS; Lee HS; Oh JM
Ann Pharmacother; 2012 Dec; 46(12):1637-44. PubMed ID: 23170032
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
